In addition, researchers reported that approximately 40% of women with pathogenic BRCA1 mutation and approximately 26% of women with pathogenic BRCA2 mutation develop secondary breast cancer in the contralateral 20 years after the first diagnosis of breast cancer [28]. This evidence concerns the gene BRCA2 and breast cancer.